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NOMENCLATURE 
 
 
FDG: Fluorodeoxyglucose 
 
 
PET: Positron Emission Tomography 
 
 
SPECT: Single Photon Emission Tomography 
 
 
MBq: Megabecquerel 
 
 
		
ABSTRACT 
 
 
Background: Positron Emission Tomography (PET) is an imaging modality that 
guides the revascularization management of patients with left ventricular systolic 
dysfunction secondary to coronary artery disease. Segments of the myocardium 
demonstrating   reduced perfusion and increased or preserved 18F- 
Fluorodeoxyglucose (18F-FDG) uptake are considered to be viable and thus suitable 
for revascularization. The aim of our study was to determine the prevalence of 
myocardial viability as determined by FDG-PET in our local cohort and to compare 
our prevalence of myocardial viability to data published elsewhere. 
 
Methods: We retrospectively reviewed 240 consecutive 99mTc-sestamibi 
myocardial perfusion Gated Single Photon Emission Tomography (SPECT) and 18F-
FDG PET reports of patients referred for evaluation of myocardial viability between 
January 2009 and June 2015. 
 
 
Results: 236 patients met the inclusion criteria. There were 194 (82.2%) males. 
The mean age was 59.1 (SD 11.0) years. A total of 4012 segments of the left 
ventricle were analyzed on the gated SPECT and reduced perfusion was noted in 
1862 (46.4%) segments. Perfusion-metabolism mismatch (viable myocardium) was 
observed  in  586  (31.5%)  out  of  1862  perfusion  defects.  The  prevalence  of 
myocardial viability in the study population was 61.4%. On the multivariate logistic 
regression model, aspirin intake [OR:0.37; CI:0.16-0.83; p=0.016] and hypertension 
[OR:0.26; CI:0.12-0.58; p=0.001] were associated with the presence of viable 
myocardium. Smoking  was  associated  with  the  likelihood  of  having  non-viable 
myocardium [OR:2.31; CI:1.01-5.29; p=0.048] 
 
Conclusion: The prevalence of myocardial viability as detected by 18F FDG PET in 
our local cohort is similar to prevalence rates reported in the developed world. 
 
 
 
 
 
1.  INTRODUCTION 
 
 
 
The incidence of coronary artery disease in sub-Saharan Africa is on the rise (1). In 
the  developed  world,  patients  presenting  with  acute  coronary  syndromes  have 
access to primary percutaneous coronary intervention (PCI) and coronary artery 
bypass grafting (CABG) timeously. This is not the case in sub-Saharan Africa, 
where a delay has been observed between the time of onset of chest pain to the 
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performance of coronary angiography (2). A need to assess for the presence of 
myocardial viability therefore  exists  in  our  clinical  setting.  A  number  of  imaging 
modalities are available for assessment of myocardial viability, namely stress 
echocardiography, cardiac magnetic resonance imaging and Positron Emission 
Tomography (3). 
 
 
Positron Emission Tomography identifies patients with myocardial contractile 
dysfunction secondary to ischaemic heart disease that is more likely to demonstrate 
an improvement in the left ventricular function after coronary revascularization (4). 
Myocytes exposed to reduced blood flow preferentially use glucose for cellular 
metabolism instead  of free fatty acids (5). The rationale for using 
fluorodeoxyglucose (FDG), a glucose analogue, is to detect glucose utilization 
in areas of the myocardium with reduced perfusion. Areas of the myocardium 
with reduced perfusion and increased or preserved 18F-FDG uptake are 
considered to represent viable tissue (6). 
 
 
Johannesburg, the economic hub of Southern Africa has a population of 
approximately 4 million. The city covers an area of 1 645 km2 (7).  A vast majority of 
people in this region rely on public health services (7).  In Johannesburg, there is 
only one public health centre equipped with PET.   
 
The aim of our study was to determine the prevalence of myocardial viability as 
determined  by  18F-FDG  PET  in  our  local  cohort  and  to  compare  our 
determined prevalence of myocardial viability to data published elsewhere.  To the 
best of our knowledge, this is the first study investigating the prevalence of 
myocardial viability using Positron Emission Tomography in the sub-Saharan African 
region. 
 
 
 
 
2.  MATERIALS AND METHODS 
 
 
2.1 Study Design and Population 
 
 
We reviewed Gated Single Photon Emission Tomography (SPECT) myocardial 
perfusion and metabolic (cardiac PET) imaging reports of 240 consecutive patients 
referred for assessment of myocardial viability between January 2009 and June 2015. 
All patients had ischaemic heart diseases as evidenced by a clinical history of 
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myocardial infarction and or coronary angiography. All patients above 18 years who 
had both the resting perfusion study with 99mTc-sestamibi and metabolic imaging with 
18F-FDG PET were included in the study. The referral centres included the Charlotte 
Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic 
Hospital and the Helen Joseph Hospital.  These centres are all part of the clinical 
academic complexes of the University of the Witwatersrand.  Ethics approval was 
sought from the University of the Witwatersrand Human Research Ethics Committee 
and relevant hospital authorities. 
 
2.1.1  Resting Gated SPECT Myocardial Perfusion Data and Cardiac PET Data: 
 
 
Prior to the acquisition of gated SPECT images, patients received an empiric dose 
between 555-1110 megabecquerels (MBq) of 99mTc-sestamibi intravenously. After a 
delay of approximately 60 minutes, supine myocardial perfusion images were 
acquired with a dual head gamma camera (General Electric Hawkeye; GE) equipped 
with a low energy high resolution collimator. 
 
We reviewed resting myocardial perfusion reports and documented demographic 
data, risk factors for coronary artery disease, the status of the left ventricle chamber 
(normal or dilated), segments of the myocardium with evidence of perfusion defects, 
the resting left ventricular ejection fraction (LVEF) and evidence of regional wall 
motion abnormalities. A 17-segment model was used to document the presence of 
perfusion defects and both visual and quantitative analysis were used to report on 
the presence of perfusion defects.  Patients with evidence of transmural perfusion 
defects demonstrating contractile dysfunction were selected for further imaging using 
Positron Emission Tomography. 
 
Prior to the acquisition of cardiac PET images, patients were requested to fast 
overnight. On the day of the study, all patients received 25-75 g of dextrose 
monohydrate glucose powder (Medicolab) orally. This was done to stimulate the 
endogenous release of insulin, and thus enhance FDG uptake by the myocytes. 
Thereafter, an intravenous dose of 18F-FDG between 185-370 MBq was 
administered.  After a delay of approximately 45-60 minutes from the time of 
tracer injection, a Siemens  Biograph  Somaton  Sensation  40  PET/CT  camera  
was  used  for the acquisition of images. From the cardiac PET data, we 
documented the patients’ serum glucose levels before and after oral glucose loading, 
and the presence of metabolic defects. We compared each segment with reduced 
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perfusion on Gated SPECT with cardiac PET findings to assess for perfusion-
metabolism match or mismatch.  Based  on  the  conclusion  available  from  the  
reports  sent  to  the cardiologist, we classified patients into two groups, one group 
with evidence of viable segments of the myocardium and another group without any 
viable segments. 
 
2.1.2  Coronary Angiography 
 
 
Coronary angiography data was available in 145 (61.4%) patients. The data was 
obtained from study requisition forms, angiogram reports and patient discharge 
summaries. Where  reported  coronary  angiography  data  was  not  available,  the 
archived coronary angiogram cine images were retrieved and reviewed by an 
independent cardiologist, blinded to the myocardial viability results. 
 
2.2 Statistical Analysis 
 
 
The statistical analyses were generated using STATA MP version 13.0 (StataCorp, 
Texas). Normally distributed continuous variables were summarized as mean and 
standard deviation, whereas for the non-normally distributed data, the median and 
interquartile range was used. The Chi- square test was used to compare categorical 
variables. Both univariate and multivariate logistic regression analyses were done. 
We included the following parameters: age, gender, ethnicity, hypertension, diabetes 
mellitus, dyslipidaemia, smoking, family history of coronary artery disease, the size 
of the left ventricle lumen at rest, regional wall motion abnormalities and concomitant 
oral medication. Pearson’s correlation was utilized to find a relationship between two 
groups.  Differences were considered statistically significant at a p value of < 0.05. 
Confidence intervals were calculated at 95% interval levels. 
 
 
 
 
 
 
 
3.  RESULTS 
 
 
The study population comprised of 236 patients. Out of 240 consecutive reports 
reviewed, four patients were excluded from the study. One patient had viability 
assessment performed after the administration of Thallium-201 chloride and another 
patient had a resting perfusion study done outside the academic sector.  The other 
two patients had reports with inconclusive findings. 
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There were 194 (82.2%) males. The mean age was 59.1 (SD 11.0) years. The 
majority, 53.0% of the study population were classified as white and 30.1% were 
Indian. There were 32 (13.6%) study participants classified as black. Hypertension 
was the most common risk factor for coronary artery disease. This finding was 
observed in 48.3% of the participants. In this cohort, there were only 4 patients 
reported to have a history of infection with Human Immunodeficiency Virus (HIV) 
(Table 1). 
 
Overall, 145 (61.4%) patients had evidence of viable myocardium and 55.5% of the 
patients had evidence of viability in more than 10% of the myocardium (17 segment 
model). 
 
A total of 4012 segments of the left ventricle were analyzed for the presence of 
perfusion defects. Reduced perfusion was noted in 1862 (46.4%) segments. A 
perfusion-metabolism mismatch (viable myocardium) pattern was evident in 586 out 
of 1862 segments (31.5%). The basal inferoseptal (p=0.021) and mid inferior 
(p=0.030) segments were the only two segments associated with the presence of 
viable myocardium (Table 2). Seventy percent of the patients in the study population 
had a dilated left ventricle at rest. 
 
The mean resting LVEF on Gated SPECT was 28.9% (SD 11.4) One hundred and 
sixty-eight (71.2%) patients had a resting LVEF less than or equal to 35% and 19.9% 
had a LVEF between 36-49%. There were 15 patients with normal resting LVEF. 
The LVEF was not available in 6 patients, due to gating errors. Global hypokinesia 
was observed in 52.2%, akinesia in 27.5% and dyskinesia in 34.0%.  The dyskinetic 
segments were seen in 70.0% of patients with resting LVEF less than or equal to 
35%. 
 
 
Angiographic data was available in 145 (61.4%) patients.  Sixty (41.4%) had triple 
vessel disease, 37.9% had double vessel disease and 20.7% had single vessel 
disease. The left anterior descending artery was diseased in 54.2%, the right 
coronary artery in 48.7% and the left circumflex in 31.4%. 
 
One hundred and three patients (43.6%) were taking oral beta-blocker medication, 
 
40.3% were on statins, 26.3% were on calcium antagonists, 19.1% were on oral 
nitrates and 42.0% were taking aspirin. 
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Multivariate logistic regression analyses showed an association between aspirin 
intake [OR:0.37; CI:0.16-0.83; p=0.016] and the presence of viable myocardium.  An 
association was also noted between hypertension [OR: 0.26; CI:0.12-0.58; p=0.001] 
and the presence of myocardial viability.  Smoking was associated with the likelihood 
of having non-viable myocardium [OR: 2.31; CI:1.01-5.29; p=0.048] (Table 3).  
 
 
 
 
 
4.  DISCUSSION 
 
 
The prevalence of myocardial viability in our local cohort is similar to prevalence rates 
reported in the developed world.  This is despite limited access to resources in our 
clinical setting. Schinkel et al. assessed the prevalence of myocardial viability in a 
population in Netherlands and reported a prevalence of 61% (8). The matching 
prevalence rates are likely related to the comparable patient characteristics such as 
the mean age, the predominance of white race in our cohort and the proportion of 
patients with a LVEF less than or equal to 35%. Similarly, Auerbach et al. reported a 
prevalence of 55% elsewhere in the developed world (9). 
 
Hypertension was the most common risk factor for coronary artery disease. We 
noted that patients with hypertension were more likely to have viable myocardium. 
The hypertrophied heart, which is commonly seen in hypertensive patients has been 
found to demonstrate an impairment in energy metabolism, which may manifest as 
increased glucose utilization and glycolysis (10). Furthermore the sub-endocardial 
region of the myocardium in hypertensive patients  is prone to ischaemia as a result 
of a blunted or absent coronary vasodilatory reserve (11). We hypothesize that this 
region could possibly hibernate and survive on less oxygen supply, thus protecting it 
in the event of occlusive coronary artery disease.  
 
 
Smoking is another well-established independent risk factor for cardiovascular 
disease. Our study demonstrated that smokers were twice as likely to have non- 
viable myocardium.  This finding enforces the need to implement smoking cessation 
programs in smokers with coronary artery disease, more importantly before any 
revascularization techniques. There was no association between the presence of 
non-viable myocardium and diabetes mellitus, dyslipidaemia and a family history of  
coronary artery disease. 
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The contribution of the Human Immunodeficiency virus to the burden of coronary 
artery disease in sub-Saharan Africa remains relatively small (12). In our study, 
there were only 4 (1.7%) patients with HIV. To the best of our knowledge, there has 
been no study demonstrating a higher prevalence of coronary artery disease in 
patients with HIV in South Africa despite a growing volume of data confirming this 
association in the developed world (13, 14). 
 
 
This  study  has  supported  the  benefit  of  Aspirin  intake  in  patients  known  with 
coronary artery disease. Aspirin prevents arterial thrombosis and the occurrence of 
serious vascular events (15). In our study, patients taking Aspirin were more likely to 
have viable myocardium, compared to patients not on Aspirin. 
 
 
In our resource-poor setting, it would have been ideal to find parameters on Gated 
SPECT myocardial perfusion imaging that could allow us to select patients for further 
imaging with PET. This study failed to demonstrate parameters on perfusion imaging 
that could independently predict the presence of viable myocardium. Nevertheless, 
we noted that the basal inferoseptal and mid inferior segments were more likely to 
have viable myocardium. 
 
 
The main limitation of this study is its retrospective nature. Data was collected from 
clinical  records  and  imaging  reports.  Some of the important risk factors 
associated with coronary artery diseases such as obesity, could not be assessed. 
Secondly, the  inter-observer  variability  among  the Nuclear Physicians in our 
department may have also affected the imaging findings documented on the imaging 
reports. Lastly, the presence of viable myocardium was solely considered on the 
observation of the perfusion-metabolism mismatch pattern. An ideal end-point would 
have been a prospective follow-up of these patients to establish how many had an 
improvement in their anginal symptoms and or left ventricular systolic function 
following revascularization if done.  
 
 
5.  CONCLUSION 
 
 
The prevalence of myocardial viability as detected by 18F FDG PET in our local cohort 
is 61.4%. This suggests that two-thirds of our population could potentially benefit 
from revascularization. This finding supports the clinical utility of PET in our setting. 
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Figure 1 
Flow chart outlining left ventricular segment analysis 
 	
Patients recruited into the study meeting the inclusion criteria  
(n=236) 
 
Number of segments analyzed (17 segment model) 
(n=4 012) 
Segments with reduced 
perfusion 
(n=1 862) 
 
Perfusion-metabolism match 
(non-viable segments) 
(n=1 276) 
 
Perfusion-metabolism mismatch  
(viable segments) 
(n= 586) 
 
Segments without 
reduced perfusion 
(n=2 150) 
 
99mTc-sestamibi Gated SPECT myocardial perfusion and 18F-FDG Cardiac PET 
reports of consecutive patients from January 2009 and June 2015 
(n=240) 
 
		 
 
 
Table 1 
Baseline characteristics of patients according to myocardial viability 
 
 
Variable  Overall population (n=236)  Myocardial viability  p-value 
 
 No (n=91) (38.6%) Yes (n=145) (61.4%)  
Age (years) 59.1  SD 11.0 57.7 SD 11.4 60.0 SD 10.7 0.163 
 
20-39 
 
11 (4.7) 
 
5   (5.5) 
 
6 (4.1)  
 
40-49 
 
36  (15.3) 
 
16 (17.6) 
 
20 (13.8)  
 
50-59 
 
70 ( 29.7) 
 
33 (36.3) 
 
37 (25.5)  
 
60-69 
 
78  (33.1) 
 
22 (24.2) 
 
56 (38.6)  
 
70+ 
 
41 (17.4) 
 
15 (16.5) 
 
26 (17.9)  
 
Male 
 
194 (82.2) 
 
75 (82.4) 
 
119 (82.1) 
 
0.524 
 
Ethnicity:    
 
0.164 
 
White 
 
125 (53.0) 
 
56 (61.5) 
 
69 (47.6)  
 
Indian 
 
71 (30.1) 
 
21 (23.1) 
 
50 (34.5)  
 
Black 
 
32 (13.6) 
 
12 (13.2) 
 
20 (13.8)  
 
Cardiovascular risk factors:     
 
Hypertension 
 
114 (48.3) 
 
33 (36.3) 
 
81 (55.9) 
 
0.003 
 
Diabetes Mellitus 
 
61 (25.9) 
 
17 (18.7) 
 
44 (30.3) 
 
0.046 
 
Dyslipidaemia 
 
91 (38.6) 
 
28 (30.8) 
 
63 (43.5) 
 
0.051 
		 
 
 
Smoking 91 (38.6) 34 (37.4) 57 (39.3) 0.765 
 
Family history of CAD 
 
58 (24.6) 
 
17 (18.7) 
 
41 (28.3) 
 
0.096 
 
HIV 
 
4  (1.7) 
 
2   (2.2) 
 
2   (1.4) 
 
0.635 
 
Concomitant medication:     
 
Beta Blockers 
 
103 (43.6) 
 
29 (31.9) 
 
74 (51.0) 
 
0.004 
 
Aspirin 
 
99 (42.0) 
 
27 (29.7) 
 
72 (49.7) 
 
0.002 
 
Statins 
 
95 (40.3) 
 
27 (29.7) 
 
68 (46.9) 
 
0.009 
 
ACE Inhibitor 
 
76 (32.2) 
 
24 (26.4) 
 
52 (35.9) 
 
0.129 
 
Calcium Channel Blocker 
 
62 (26.3) 
 
19 (20.9) 
 
43 (29.7) 
 
0.136 
 
Nitrates 
 
45 (19.1) 
 
13 (14.3) 
 
32 (22.1) 
 
0.138 
 
Regional wall motion:     
 
Akinesia 
 
65 (27.5) 
 
29 (31.9) 
 
36 (24.8) 
 
0.239 
 
Dyskinesia 
 
80 (34.0) 
 
24 (26.4) 
 
56 (38.6) 
 
0.053 
 
Global hypokinesia 
 
124 (52.5) 
 
49 (53.9) 
 
75 (51.7) 
 
0.751 
 
Resting LVEF (SPECT):  28.9 SD 11.4 27.1 SD 10.4 30 SD 11.8 0.123 
 
LVEF ≥ 50 
 
15   (6.4) 
 
4 
 
(4.4) 
 
11   (7.6)  
 
LVEF = 41-49 
 
25 (10.6) 
 
5 
 
(5.5) 
 
20 (13.8)  
 
LVEF = 36-40 
 
22   (9.3) 
 
8 
 
(8.8) 
 
14   (9.7)  
 
LVEF ≤ 35 
 
168 (71.2) 
 
70 
 
(76.9) 
 
98 (67.6)  
		 
 
 
 
 
 
 
Data are shown as mean, standard deviation (SD) for continuous variables and absolute numbers (percentage) for dichotomous variables. 
 
CAD: coronary artery disease; ACE: HIV: Human Immunodeficiency Virus; Angiotensin Converting Enzyme; SPECT: single photon emission tomography; LVEF: left 
ventricular ejection fraction 
		 
 
 
Table 2 
Segments with viable myocardium 
 
 
Segment  Overall population 
(n=236) 
Myocardial viability  p-value 
 
No (n=91) (38.6%)  Yes (n=145 ) (61.4%) 
 
Apex 187 (79.2) 67 (73.6) 120 (82.8) 0.092 
 
Anterior wall:       
 
Apical anterior 
 
163 
 
(69.1) 
 
60 
 
(65.9) 
 
103 (71.0) 
 
0.409 
 
Mid anterior 
 
136 
 
(57.6) 
 
48 
 
(52.8) 
 
88 (60.7) 
 
0.229 
 
Basal anterior 
 
55 
 
(23.3) 
 
17 
 
(18.7) 
 
38 (26.2) 
 
0.183 
 
Septal wall:       
 
Apical septal 
 
121 
 
(51.3) 
 
49 
 
(53.9) 
 
72 (49.7) 
 
0.531 
 
Mid anteroseptal 
 
132 
 
(55.9) 
 
48 
 
(52.8) 
 
84 (57.9) 
 
0.435 
 
Basal anteroseptal 
 
91 
 
(38.6) 
 
30 
 
(33.0) 
 
61 (42.1) 
 
0.162 
 
Mid inferoseptal 
 
111 
 
(47.0) 
 
39 
 
(42.9) 
 
72 (49.7) 
 
0.308 
 
Basal inferoseptal 
 
100 
 
(42.4) 
 
30 
 
(33.0) 
 
70 (48.3) 
 
0.021 
 
Lateral wall:       
 
Apical lateral 
 
79 
 
(33.5) 
 
26 
 
(28.6) 
 
53 (36.6) 
 
0.206 
 
Mid anterolateral 
 
47 
 
(19.9) 
 
16 
 
(17.6) 
 
31 (21.4) 
 
0.477 
 
Basal anterolateral 
 
29 
 
(12.3) 
 
8 
 
(8.8) 
 
21 (14.5) 
 
0.195 
		 
 
Mid inferolateral 69 (29.2) 23 (25.3) 46 (31.7) 0.289 
 
Basal inferolateral 
 
70 
 
(29.7) 
 
23 
 
(25.3) 
 
47 (32.4) 
 
0.243 
 
Inferior wall:       
 
Apical inferior 
 
194 
 
(82.2) 
 
75 
 
(82.4) 
 
119 (82.1) 
 
0.946 
 
Mid inferior 
 
145 
 
(61.4) 
 
48 
 
(52.8) 
 
97 (66.9) 
 
0.030 
 
Basal inferior 
 
133 
 
(56.4) 
 
45 
 
(49.5) 
 
88 (60.7) 
 
0.090 
 
 
Data shown as absolute numbers (percentage) 
 Table 3 
 
Multivariable Logistic Regression Analysis 
Independent predictors of myocardial viability 
 
 
 
 
Variables OR 95% CI Z p-value 
Hypertension 0.26 0.12 – 0.58 -3.28 0.001 
 
Diabetes mellitus 
 
0.75 
 
0.30 – 1.86 
 
-0.62 
 
0.534 
 
Dyslipidaemia 
 
0.94 
 
0.41 – 2.18 
 
-0.14 
 
0.890 
 
Smoking 
 
2.31 
 
1.01 – 5.29 
 
1.98 
 
0.048 
 
Family history of CAD 
 
0.81 
 
0.32 – 2.02 
 
-0.45 
 
0.650 
 
Aspirin 
 
0.37 
 
0.16 – 0.83 
 
-2.40 
 
0.016 
 
Dyskinesia 
 
0.50 
 
0.23 – 1.07 
 
-1.80 
 
0.073 
 
CAD; coronary artery disease 
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1. INTRODUCTION 
 
 
The ability of cardiac myocytes to reduce the contractile function of the heart in 
states of chronic hypoperfusion after myocardial infarction, and recover after 
restoration of optimal blood flow is a well described phenomenon, with the coined 
term of “hibernating myocardium.”  Coronary revascularization, either percutaneously 
or with coronary artery bypass grafting (CABG) of patients with hibernating 
myocardium has been associated with an improvement in anginal symptoms and 
symptoms of heart failure as well as a decline in the number of hospitalization of 
patients with heart failure secondary to chronic coronary artery disease 1. The 
accurate identification of such patients is crucial. 
 
 
 
The cardiology units at Charlotte Maxeke Johannesburg Academic Hospital, Chris 
 
Hani Baragwanath Academic Hospital and Helen Joseph Hospitals refer patients 
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who have had a myocardial infarction (MI) to the Department of Nuclear Medicine at 
Charlotte Maxeke Johannesburg Academic Hospital, which is the only public hospital 
in Johannesburg equipped with a Positron Emission Tomography (PET) scan, for 
assessment of myocardial viability. 
 
Positron Emission Tomography identifies patients with myocardial contractile 
dysfunction, who are likely to demonstrate an improvement in the left ventricular 
ejection fraction after coronary revascularization. Hibernating cells, with reduced 
perfusion, preferentially use glucose for cellular metabolism instead of free fatty 
acids. Areas within the myocardium with  increased or normal 18F- 
Fluorodeoxyglucose (F18-FDG) uptake signify the presence of viable tissue 2. 
 
Prior to acquisition of PET images, patients will initially have myocardial perfusion 
imaging, which is performed with a gamma camera using Gated Single Photon 
Emission Tomography (Gated SPECT). During a rest study, Technetium-99m 
methoxy-isobutyl-isonitrile (MIBI) is administered intravenously, as the name implies, 
under rest conditions. Subsequently, patients are imaged with a gamma camera 
using gated SPECT. The technetium labelled tracer enters the cardiac myocytes by 
passive diffusion and localize in the cytoplasmic mitochondria and thereafter remain 
fixed within the mitochondria 3. 
 
 
In circumstances where the presence of myocardial ischaemia along with viability is 
questioned, an exercise stress test may be performed with a treadmill or with 
pharmacological agents that induce hyperaemia in coronary arteries or increase the 
rate of contractility.  The visualization of perfusion defects on the perfusion images is 
subsequently followed by assessment of viability 4, 5,6. 
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In contrast to the technetium labelled tracers, Thallium-201, a radionuclide that is 
also employed when imaging with gated SPECT, requires intact cellular membrane 
integrity to be able to localize in the myocytes7.  Thallium enters the myocytes via the 
Na+/K+  pump. It is on such basis that assessment of viability is achievable with 
 
Thallium.  The disadvantages of using Thallium include lower photon energy of 80 
keV, making it an unfavourable tracer in imaging obese patients due to soft tissue 
attenuation of the photons.  Thallium also has a higher radiation burden, thus limiting 
the amount of administered dose to 1 mCi (37 MBq).   This undoubtedly results in 
poor spatial resolution. 
 
Positron emission tomography blood flow tracers are used to assess myocardial 
blood flow, prior to assessment of cellular metabolism. However, these tracers are 
used in centres equipped with on-site cyclotrons as they have short physical half- 
lives or require frequent replacement of generators producing these radionuclides. In 
a retrospective study involving 283 patients with ischaemic cardiomyopathy, referred 
for myocardial viability imaging with 13N ammonia/18F FDG PET, the prevalence of 
 
myocardial viability was 55% 8. 
 
 
Other modalities available for the assessment of myocardial viability include 
echocardiography and cardiac magnetic resonance imaging (CMR) 7. Two- 
dimensional echocardiography assesses myocardial viability by assessing the 
response of contractile function to ionotropic stimulation after administering a low 
dose  Dobutamine  infusion  intravenously.  Improvement  of  baseline  contractile 
function after the infusion, signifies viable myocardium 9. Other parameters on 
echocardiography that are used to assess viability of myocytes are wall thickness, 
mitral deceleration time and strain rate7. 
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Cardiac Magnetic Resonance imaging, along with the use of either Dobutamine or 
Gadolinium can differentiate between viable and infarcted myocytes.  Gadolinium is 
an  extracellular  molecule,  which  does  not  cross  intact  cellular  membranes. 
However, in conditions that disrupt the cellular membrane, such as myocardial 
infarction,  accumulation  and  reduced  washout  of  Gadolinium  is  seen  in  the 
intracellular environment, a hallmark of infarcted tissue 10. 
 
 
Petrucci  et  al  in  a  prospective  study,  assessed  areas  of  scar  tissue  in  the 
myocardium manifesting as delayed Gadolinium enhancement on CMR with 
intracoronary  electrograms  recorded  during  percutaneous  coronary  intervention. 
They concluded that intracoronary electrograms, based on voltage amplitude, could 
discriminate between viable and non-viable myocardium 11. 
 
Failure to perform coronary revascularization is associated with higher morbidity and 
mortality rates, in comparison to groups with viable myocardium who are treated with 
medical therapy. In a meta-analysis involving 3 088 patients, patients with viable 
myocardium, who were revascularized had an annual mortality rate of only 3.2% 
compared to those treated medically, with an annual mortality rate of 16% 12. 
 
The CMJAH nuclear medicine unit performs cardiac PET scans for patients in the 
Johannesburg  Metropolitan.  However,  our  local  prevalence  rate  of  myocardial 
viability has never been determined. 
 
STUDY OBJECTIVES 
Primary objectives: 
a)  To estimate the prevalence of myocardial viability as determined by PET. 
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b)  To  compare  our  prevalence  rate  of  myocardial  viability  to  published 
data/literature. 
 
 
 
Secondary objective: 
 
c)  To describe the characteristics of patients referred for myocardial viability 
imaging. 
 
 
 
2.  METHODS 
 
3.1 Study Design 
 
 
This  is  a  retrospective  review  of  Tc-99m  sestamibi  and  F18-FDG  PET  cardiac 
reports of patients who were referred for myocardial viability assessment between 
January  2009  and  June  2015  at  Charlotte  Maxeke  Johannesburg  Academic 
Hospital. 
 
3.2 Study Population, sampling and protocol 
 
 
This study will be conducted at the Department of Nuclear Medicine. Electronic 
version and hard copies, where available of the Tc-99m sestamibi and F18-FDG 
PET  cardiac  reports  of  the  consecutive  patients  referred  for  assessment  of 
myocardial viability will be reviewed. The sample size will be dependent on the total 
number of patients referred for myocardial viability assessment between January 
2009 and June 2015. We usually see about 32 patients on a yearly basis. A 
 
minimum of 230 patients will be reviewed. 
 
 
3.3 Inclusion Criteria 
 
 
a)  Age > 18 years 
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b)  Patients that had both a rest 99mTc sestamibi and 18F FDG PET scan 
performed for assessment of myocardial viability. 
 
 
 
 
 
3.4 Exclusion Criteria 
 
 
a)  Studies with incomplete data or missing variables. 
 
 
3.5 Materials 
 
 
The following variables, which will appear on the Tc-99m sestamibi and F18-FDG 
PET cardiac reports and clerking notes, will be recorded on RedCap data collection 
sheet (see attached appendix). 
 
3.5.1 Demographics 
 
 
Age (years), gender, ethnicity, weight (kg) and height (cm) 
 
 
3.5.2  Risk factors (for coronary artery disease) and Co-morbidities 
 
 
The following conditions will be considered for analysis: Diabetes, Hypertension, 
Chronic kidney disease, HIV, Peripheral vascular disease, Dyslipidaemia, Family 
history of ischaemic heart disease, previous myocardial infarction, smoking, 
Asthma and Chronic obstructive airway disease. 
 
3.5.3  Concomitant medication 
 
 
B-blockers, aspirin, Angiotensin Converting Enzyme Inhibitors, Calcium channel 
blockers, nitrates and statins. 
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3.5.4  F18-FDG cardiac PET findings 
 
 
We will document all the following parameters of the PET findings: dose of oral 
glucose administered, minutes between tracer injection and image acquisition, 
serum glucose levels, segments showing improvement on cardiac PET, % 
recoverable total myocardium and % recoverable infarcted area. 
 
 
 
 
 
3.5.5  Tc-99m sestamibi myocardial perfusion imaging findings 
 
 
Similar to PET findings, we will also document the following parameters for gated 
SPECT: radionuclide employed, nitrate enhancement, type of exercise stress 
test, resting and stress systolic and diastolic pressures, pharmacological agents 
used and changes in heart rate response, evidence of perfusion defects, left 
ventricular ejection fraction and evidence of regional wall motion abnormalities. 
 
3.5.6  Angiographic findings 
 
 
Angiographic findings pertaining to the diseased vessel will be documented. 
 
 
 
 
 
 
3.6  Data management and analysis 
 
 
Descriptive statistics-frequency tables will be used to describe demographic and 
clinical parameters. Multivariate analysis of risk factors will be done. Chi-test and 
Fisher’s exact will be used to compare categorical variables. Continuous variables 
will be summarized as mean +/- SD of median and Inter quartile range for non- 
normality distribution of the data. Student t- test and Wilcoxon rank sum test will be 
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used. STATA version 11 will be used for the data analysis. 95% confidence interval 
will be calculated for all data. 
 
4. ETHICS AND CONFIDENTIALITY 
 
 
This study will be conducted at Charlotte Maxeke Academic Hospital in the 
Department of Nuclear Medicine in fulfilment of the requirements of the Masters in 
Medicine research report. Ethics approval will be sought from the University of 
Witwatersrand Human Research Ethics Committee and relevant hospital authorities. 
Unique patient identifiers will be used on the data collection sheet to protect the 
identity of the study participants. Outcomes will be published in a peer review journal 
and will be used to make recommendations whenever necessary, and/or required. 
 
 
 
 
 
5. TIMING 
 
 
TASKS PROPOSED COMPLETION DATE 
Protocol assessment July 2015 
Ethics Application August 2015 
Data Collection August 2015 to September 2015 
Data analysis October to November 2015 
Write up December to January 2016 
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6. FUNDING 
 
 
This study is a low cost research project. Funding will not be required. 
Photocopying and printing cost will be paid by myself. 
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paper text: 
Background: 
 
 
2Positron Emission Tomography (PET) is an imaging 
 
 
modality that guides the revascularization 
 
 
7management of patients with left ventricular systolic dysfunction secondary to 
 
coronary artery disease. 
 
 
Segments of the myocardium demonstrating reduced perfusion and increased or preserved 18F- 
Fluorodeoxyglucose (18F-FDG) uptake are considered to be viable and thus suitable for revascularization. 
The 
 
 
2aim of our study was to determine the prevalence of myocardial 
 
 
viability as determined by FDG-PET in an African population and to compare our prevalence of myocardial 
viability to data published elsewhere. Methods: We retrospectively reviewed 240 99mTc-sestamibi 
 
 
2myocardial perfusion Gated Single Photon Emission Tomography (SPECT) 
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and 18F-FDG PET reports of patients referred for evaluation of myocardial viability between January 2009 
and June 2015. Results: 236 patients met the inclusion criteria. There were 194 (82.2%) males. The mean 
age was 59.1 (SD 11.0) years. A total of 4012 segments of the left ventricle were analyzed on the gated 
SPECT and reduced perfusion was noted in 1862 (46.4%) segments. Perfusion-metabolism mismatch 
(viable myocardium) was observed in 586 (31.5%) out of 1862 perfusion defects. The prevalence of 
myocardial viability in the study population was 61.4%. On the multivariate logistic regression model, aspirin 
intake [OR:0.37; CI:0.16-0.83; p=0.016] and hypertension [OR:0.26; 
 
 
6CI:0. 12 -0. 58; p=0. 001] were associated with 
 
 
the presence of viable myocardium. Smoking was associated with the likelihood of having non-viable 
myocardium [OR:2.31; CI:1.01-5.29; p=0.048] Conclusion: The 
 
 
3prevalence of myocardial viability as detected by 18F FDG PET in 
 
 
our African cohort is similar to prevalence rates reported in the developed world. 1. INTRODUCTION The 
incidence of coronary artery disease in sub-Saharan Africa is on the rise (1). In the developed world, 
 
 
30patients presenting with acute coronary syndromes 
 
 
have access to primary 
 
 
17percutaneous  coronary intervention (PCI) and coronary artery bypass 
grafting (CABG) timeously. This is not the 
 
 
case in sub-Saharan Africa, where a delay has been observed between the time of 
 
 
1onset of chest pain to the performance of coronary angiography 
 
 
(2). A need to assess for the presence of myocardial viability therefore exists in our clinical setting. A number 
of imaging modalities are available for assessment of myocardial viability, namely 
 
 
3stress echocardiography, cardiac magnetic resonance imaging and Positron 
 
Emission Tomography 
 
 
(3). Positron Emission Tomography identifies patients with myocardial contractile dysfunction secondary to 
ischaemic heart disease that is more likely to demonstrate an improvement in the left ventricular function 
after coronary revascularization (4). Myocytes exposed to reduced blood flow preferentially use glucose for 
cellular metabolism instead of free fatty acids (5). The rationale for using fluorodeoxyglucose (FDG) a 
glucose analogue, is to detect glucose utilization 
 
 
14in areas of the myocardium with reduced perfusion. 
 
 
 
 
14Areas of the myocardium with reduced perfusion 
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and increased or preserved 18F-FDG uptake are considered to represent viable tissue (6). Johannesburg, 
the economic hub of Southern Africa has a population of ~ 4 million. The city covers an area of 1 645 km2 
(7). A vast majority of people in this region rely on public health services (7). In Johannesburg, there is only 
one public health centre equipped with PET. Despite this resource constraint, the majority of patients in 
Johannesburg requiring assessment of myocardial viability are imaged with PET. The 
 
 
2aim of our study was to determine the prevalence of myocardial 
 
 
viability as determined by 18F-FDG PET in an African population and to compare our determined 
prevalence of myocardial viability to data published elsewhere. 
 
 
13To the best of our knowledge, this is the first systematic study investigating 
 
the prevalence of 
 
 
myocardial viability using Positron Emission Tomography in an African cohort. 
 
 
182. MATERIALS AND METHODS 2.1 Study Design and Population We 
 
 
reviewed 
 
 
2Gated Single Photon Emission Tomography (SPECT) myocardial perfusion 
 
 
and metabolic (cardiac PET) imaging reports of 240 consecutive patients 
 
 
6referred for assessment of myocardial viability 
 
 
 
 
6between January 2009 and June 2015. All patients had 
 
 
ischaemic heart diseases as evidenced by a clinical history of 2 myocardial infarction and or coronary 
angiography. All patients above 18 years who had both the resting perfusion study with 99mTc-sestamibi 
and metabolic imaging with 
 
 
518F-FDG PET were included in the study. 
 
 
The referral centres included 
 
 
8the Charlotte Maxeke Johannesburg  Academic Hospital, Chris Hani 
 
Baragwanath Academic Hospital and the Helen Joseph Hospital. 
 
 
These centres are all part of the clinical academic complexes of the University of Witwatersrand. Ethics 
approval was sought 
 
 
20from the University of Witwatersrand  Human Research Ethics Committee 
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and relevant hospital authorities. 2.1.1 Resting Gated SPECT Myocardial Perfusion Data and Cardiac PET 
Data: Prior to the acquisition of gated SPECT images, patients received an empiric dose between 555-1110 
megabecquerels (MBq) of 99mTc-sestamibi intravenously. After a delay of ~ 60 minutes, supine myocardial 
perfusion images were acquired with 
 
 
9a dual head gamma camera (General Electric Hawkeye; GE) equipped with a 
low energy high resolution collimator. 
 
 
We reviewed resting myocardial perfusion reports and documented demographic data, 
 
 
2risk factors for coronary artery disease, 
 
 
the status of the left ventricle chamber (normal or dilated), segments of the myocardium with evidence of 
perfusion defects, the resting left ventricular ejection fraction (LVEF) and evidence of regional wall motion 
abnormalities. A 17-segment model was used to document the presence of perfusion defects and both visual 
and quantitative analysis were used to report on the presence of perfusion defects. Patients with evidence of 
transmural perfusion defects demonstrating contractile dysfunction were selected for further imaging using 
Positron Emission Tomography. Prior to the acquisition of cardiac PET images, patients were requested to 
fast overnight. On the day of the study, all patients received 25-75 g of dextrose monohydrate glucose 
powder (Medicolab) orally. This was done to stimulate the endogenous release of insulin, and thus enhance 
FDG uptake by the myocytes. Thereafter, an intravenous dose of 18F-FDG between 185-370 MBq was 
administered. After a delay of ~ 45-60 minutes from the time of tracer injection, a Siemens Biograph 
Somaton Sensation 40 PET/CT camera was used for the acquisition of images. From the cardiac PET data, 
we documented the patient's 3 serum glucose levels before and after oral glucose loading, and the presence 
of metabolic defects. We compared each segment with reduced perfusion on Gated SPECT with cardiac 
PET findings to assess for perfusion-metabolism match or mismatch. Based on the conclusion available from 
the reports sent to the cardiologist, we classified patients into two groups, one group with evidence of viable 
segments of the myocardium and another group without any viable segments. 2.1.2 Coronary Angiography 
Coronary angiography data was available in 145 (61.4%) patients. The data was obtained from study 
requisition forms, angiogram reports and patient discharge summaries. Where reported coronary 
angiography data was not available, the original coronary angiogram was retrieved and reviewed from the 
angiography suite data archives by a qualified cardiologist. 
 
 
12.2 Statistical Analysis The statistical analyses were generated using STATA 
MP version 13. 0 (StataCorp, Texas). Normally distributed continuous variables 
were summarized as mean and standard deviation 
 
 
whereas, for the non-normally distributed data, the 
 
 
11median and interquartile range was used. The Chi- square test was used to 
compare categorical variables. 
 
 
 
1Both univariate and multivariate logistic regression analyses were done. We 
included the following parameters: 
 
 
age, gender, ethnicity, hypertension, diabetes mellitus, dyslipidaemia, smoking, family history 
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4of coronary artery disease, the size of the 
 
 
left ventricle lumen at rest, regional wall motion abnormalities and concomitant oral medication. Pearson’s 
correlation was utilized to find a relationship 
 
 
15between two groups. Differences were considered statistically significant 
 
at a p value of <0.05. 
 
 
Confidence intervals were calculated at 95% interval levels. 3. RESULTS The study population comprised of 
236 patients. Out of 240 consecutive reports reviewed, four patients were excluded from the study. One 
patient had viability assessment performed after the administration of Thallium-201 chloride and another 
patient had a resting perfusion study done outside the academic sector. The other two patients had reports 
with inconclusive findings. 4 There were 194 (82.2%) males. The mean age was 59.1 (SD 11.0) years. The 
majority, 53.0% of the study population were classified as white and 30.1% were Indian. There were 32 
(13.6%) study participants classified as black. Hypertension was the most common risk factor for coronary 
artery disease. This finding was observed in 48.3% of the participants. In this cohort, there were only 4 
patients reported to have a history of infection with Human Immunodeficiency Virus (HIV) (Table 1). Overall, 
145 (61.4%) patients had evidence of viable myocardium and 55.5% of the patients had evidence of viability 
in more than 10% of the myocardium (17 segment model). A total of 4012 segments of the left ventricle were 
analyzed for the presence of perfusion defects. Reduced perfusion was noted in 1862 (46.4%) segments. A 
perfusion-metabolism mismatch (viable myocardium) pattern was evident in 586 out of 1862 segments 
(31.5%). The basal 
 
 
28inferoseptal (p=0. 021) and mid inferior (p=0. 
 
 
030) segments were the only two segments associated with the presence of viable myocardium (Table 2). 
Seventy percent of the patients in the study population had a dilated left ventricle at rest. The mean resting 
LVEF on Gated SPECT was 28.9% SD 11.4. One hundred and sixty-eight (71.2%) patients had a resting 
LVEF less than or equal to 35% and 19.9% had a LVEF between 36-49%. There were 15 patients with 
normal resting LVEF. The LVEF was not available in 6 patients, due to gating errors. Global hypokinesia was 
observed in 52.2%, akinesia in 27.5% and dyskinesia in 34.0%. The dyskinetic segments were seen in 
70.0% of patients with resting LVEF less than or equal to 35%. Angiographic data was available in 145 
(61.4%) patients. Sixty (41.4%) 
 
 
12had triple vessel disease, 37.9% had double vessel disease and 20.7% had 
single vessel disease. The 
 
 
left anterior descending artery was diseased in 54.2%, the 
 
 
26right coronary artery in 48.7% and the left circumflex in 
 
 
31.4%. One hundred and three patients (43.6%) were taking oral beta-blocker medication, 40.3% were on 
statins, 26.3% were on calcium antagonists, 19.1% were on oral nitrates and 42.0% were taking aspirin. 
Multivariate logistic regression analyses showed an association between aspirin intake [OR:0.37; CI:0.16- 
0.83; p=0.016] and the presence of viable myocardium. An association was also noted between 
hypertension [OR: 0.26; CI:0.12-0.58; 
 
 
16p=0.001] and the presence of myocardial viability. Smoking was associated 
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with the 
 
 
likelihood of having non-viable myocardium [OR: 2.31; CI:1.01-5.29; p=0.048] (Table 3). 4. DISCUSSION 
The prevalence of myocardial viability in our African cohort is similar to prevalence rates reported in the 
developed world. This is despite limited access to resources in our clinical setting. Schinkel et al. assessed 
the prevalence of myocardial viability in a population in Netherlands and reported a prevalence of 61% (8). 
The matching prevalence rates are likely related to the comparable patient characteristics such as the mean 
age, the predominance of white race in our cohort and the proportion of patients with a LVEF less than or 
equal to 35%. Similarly, Auerbach et al. reported a prevalence of 55% elsewhere in the developed world (9). 
Hypertension was the most common risk factor for coronary artery disease. We noted that patients with 
hypertension 
 
 
25were more likely to have viable myocardium. In patients with hypertensive heart 
 
disease, 
 
 
the sub-endocardial region of the myocardium is prone to ischaemia as a result of a blunted or absent 
coronary vasodilatory reserve (10). Our hypothesis is that this region could possibly hibernate and survive 
on less oxygen supply, thus protecting it in the event of occlusive coronary artery disease. There is thus a 
requirement for prospective studies assessing the relationship between myocardial viability and 
hypertension in an African population. Smoking is another well-established independent risk factor for 
cardiovascular disease. Our study demonstrated that smokers were twice as likely to have non- viable 
myocardium. This finding enforces the need to implement smoking cessation programs in smokers with 
coronary artery disease, more importantly before any revascularization techniques. The contribution of the 
Human Immunodeficiency virus to the burden of coronary artery disease in sub-Saharan Africa remains 
relatively small (11). In our study, 6 there were only 4 (1.7%) patients with HIV. 
 
 
27To the best of our knowledge, there has been no study 
 
 
demonstrating a higher 
 
 
4prevalence of coronary artery disease in patients with 
 
 
HIV in South Africa despite a growing volume of data confirming this association in the developed world(12, 
13). This study has supported the benefit of Aspirin intake in patients known with coronary artery disease. 
Aspirin prevents arterial thrombosis and the occurrence of serious vascular events (14). In our study, 
patients taking Aspirin were more likely to have viable myocardium, compared to patients not on Aspirin. In 
our resource-poor setting, it would have been ideal to find parameters on Gated SPECT myocardial 
perfusion imaging that could allow us to select patients for further imaging with PET. This study failed to 
demonstrate parameters on perfusion imaging that could independently predict the presence of viable 
myocardium. Nevertheless, we noted that the basal inferoseptal and mid inferior segments were more likely 
to have viable myocardium. The main limitation of this study is its retrospective nature. Data was collected 
from clinical records and imaging reports. The inter-observer variability among the Nuclear Physicians in our 
department may have also affected the imaging findings documented on the imaging reports. Also, the 
presence of viable myocardium was solely considered on the observation of the perfusion-metabolism 
mismatch pattern. An ideal end-point would have been a prospective follow-up of these patients to establish 
how many had an improvement in their anginal symptoms and or 
 
 
29left ventricular systolic function following revascularization 
 
 
if done. 5. CONCLUSION The 
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3prevalence of myocardial viability as detected by 18F FDG PET in 
 
 
our African cohort is 61.4%. This suggests that two-thirds of our population could potentially benefit from 
revascularization. This finding supports the clinical utility of PET in our setting. The ability of cardiac 
myocytes to reduce the contractile function of the heart in states of chronic hypoperfusion after myocardial 
infarction, and recover after restoration of optimal blood flow is a well described phenomenon, with the 
coined term of “hibernating myocardium.” Coronary revascularization, either percutaneously or with coronary 
artery bypass grafting (CABG) of patients with hibernating myocardium has been associated with an 
improvement in anginal symptoms and symptoms of heart failure as well as a decline in the number of 
hospitalization 
 
 
3of patients with heart failure secondary to chronic coronary artery disease 
 
 
1. The accurate identification of such patients is crucial. The cardiology units 
 
 
10at Charlotte Maxeke Johannesburg  Academic Hospital, Chris Hani 
 
Baragwanath Academic Hospital and Helen Joseph 
 
 
Hospitals refer patients who have had a myocardial infarction (MI) 
 
 
5to the Department of Nuclear Medicine 
 
 
at 
 
 
24Charlotte Maxeke Johannesburg  Academic Hospital, which is the only public 
 
hospital in Johannesburg 
 
 
equipped with a 
 
 
5Positron Emission Tomography (PET) scan, for assessment of 
 
 
myocardial viability. Positron Emission Tomography identifies patients with myocardial contractile 
dysfunction, who 
 
 
7are likely to demonstrate an improvement in the left ventricular ejection fraction 
 
after coronary revascularization. 
 
 
Hibernating cells, with reduced perfusion, preferentially use glucose for cellular metabolism instead of free 
fatty acids. Areas within the myocardium with increased or normal 18F- Fluorodeoxyglucose (F18-FDG) 
uptake signify the presence of viable tissue 2. Prior to acquisition of PET images, patients will initially have 
myocardial perfusion imaging, which is performed with a gamma camera using 
 
 
4Gated Single Photon Emission Tomography (Gated SPECT). During a rest 
 
study, 
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Technetium-99m methoxy-isobutyl-isonitrile (MIBI) is administered intravenously, as the name implies, under 
rest conditions. Subsequently, patients are imaged with a gamma camera using gated SPECT. The 
technetium labelled tracer enters the cardiac 8 myocytes by passive diffusion and localize in the cytoplasmic 
mitochondria and thereafter remain fixed within the mitochondria 3. In circumstances where the presence of 
myocardial ischaemia along with viability is questioned, an exercise stress test may be performed with a 
treadmill or with pharmacological agents that induce hyperaemia in coronary arteries or increase the rate of 
contractility. The visualization of perfusion defects on the perfusion images is subsequently followed by 
assessment of viability 4, 5,6. In contrast to the technetium labelled tracers, Thallium-201, a radionuclide 
that is also employed when imaging with gated SPECT, requires intact cellular membrane integrity to be able 
to localize in the myocytes7. Thallium enters the myocytes via the Na+/K+ pump. It is on such basis that 
assessment of viability is achievable with Thallium. The disadvantages of using Thallium include lower photon 
energy of 80 keV, making it an unfavourable tracer in imaging obese patients due to soft tissue attenuation of 
the photons. Thallium also has a higher radiation burden, thus limiting the amount of administered dose to 1 
mCi (37 MBq). This undoubtedly results in poor spatial resolution. Positron emission tomography blood flow 
tracers are used to assess myocardial blood flow, prior to assessment of cellular metabolism. However, these 
tracers are used in centres equipped with on-site cyclotrons as they have short physical half-lives or require 
frequent replacement of generators producing these radionuclides. In a retrospective study involving 283 
patients with ischaemic cardiomyopathy, referred for myocardial viability imaging with 13N ammonia/18F FDG 
PET, the prevalence of myocardial viability was 55% 8. Other modalities available for the assessment of 
myocardial viability include echocardiography and cardiac magnetic resonance imaging (CMR) 7. Two-
dimensional echocardiography assesses myocardial viability by assessing the response of contractile function 
to ionotropic stimulation after administering a low dose Dobutamine infusion 9 intravenously. Improvement of 
baseline contractile function after the infusion, 
signifies viable myocardium 9. Other parameters on echocardiography that are used to assess viability of 
myocytes are wall thickness, mitral deceleration time and strain rate7. Cardiac Magnetic Resonance 
imaging, along with the use of either Dobutamine or Gadolinium can differentiate between viable and 
infarcted myocytes. Gadolinium is an extracellular molecule, which does not cross intact cellular 
membranes. However, in conditions that disrupt the cellular membrane, such as myocardial infarction, 
accumulation and reduced washout of Gadolinium is seen in the intracellular environment, a hallmark of 
infarcted tissue 10. Petrucci et al in a prospective study, assessed areas of scar tissue in the myocardium 
manifesting as delayed Gadolinium enhancement on CMR with intracoronary electrograms recorded during 
percutaneous coronary intervention. They concluded that intracoronary electrograms, based on voltage 
amplitude, could discriminate between viable and non-viable myocardium 11. Failure to perform coronary 
revascularization 
 
 
22is associated with higher morbidity and mortality rates, in 
 
 
comparison to groups with viable myocardium who are treated with medical therapy. 
 
 
21In a meta-analysis involving 3 088 patients, patients with 
 
 
viable myocardium, who were revascularized had an annual mortality rate of only 3.2% compared to those 
treated medically, with an annual mortality rate of 16% 12. The CMJAH nuclear medicine unit performs 
cardiac PET scans for patients in the Johannesburg Metropolitan. However, our local prevalence rate of 
myocardial viability has never been determined. STUDY OBJECTIVES Primary objectives: 10 a) To estimate 
the prevalence of myocardial viability as determined by PET. b) To compare our prevalence rate of myocardial 
viability to published data/literature. Secondary objective: c) To describe the characteristics of patients 
referred for myocardial viability imaging. 2. METHODS 3.1 Study Design This is a retrospective review of Tc-
99m sestamibi and F18-FDG PET cardiac reports of patients who were referred for myocardial viability 
assessment between January 2009 and June 2015 at Charlotte Maxeke Johannesburg Academic Hospital. 
3.2 Study Population, sampling and protocol This study will be conducted at the Department of Nuclear 
Medicine. Electronic version and hard copies, where available of the Tc-99m sestamibi and F18- FDG PET 
cardiac reports of the consecutive patients referred for assessment of myocardial viability will be 
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reviewed. The sample size will be dependent on the total number of patients referred for myocardial viability 
assessment between January 2009 and June 2015. We usually see about 32 patients on a yearly basis. A 
minimum of 230 patients will be reviewed. 3.3 Inclusion Criteria a) Age > 18 years b) Patients that had both 
a rest 99mTc sestamibi and 18F FDG PET scan performed for assessment of myocardial viability. 3.4 
Exclusion Criteria a) Studies with incomplete data or missing variables. 3.5 Materials The following variables, 
which will appear on the Tc-99m sestamibi and F18-FDG PET cardiac reports and clerking notes, will be 
recorded on RedCap data collection sheet (see attached appendix). 3.5.1 Demographics Age (years), gender, 
ethnicity, weight (kg) and height (cm) 3.5.2 Risk factors (for coronary artery disease) and Co- morbidities The 
following conditions will be considered for analysis: Diabetes, Hypertension, Chronic kidney disease, HIV, 
Peripheral vascular disease, Dyslipidaemia, Family history of ischaemic heart disease, 
previous myocardial infarction, smoking, Asthma and Chronic obstructive airway disease. 3.5.3 Concomitant 
medication B-blocker therapy 3.5.4 F18-FDG cardiac PET findings We will document all the following 
parameters of the PET findings: dose of oral glucose administered, minutes between tracer injection and 
image acquisition, serum glucose 12 levels, segments showing improvement on cardiac PET, % recoverable 
total myocardium and % recoverable infarcted area. 3.5.5 Tc-99m sestamibi myocardial perfusion imaging 
findings Similar to PET findings, we will also document the following parameters for gated SPECT: 
radionuclide employed, nitrate enhancement, type of exercise stress test, resting and stress systolic and 
diastolic pressures, pharmacological agents used and changes in heart rate response. 3.6 Data management 
and analysis Descriptive statistics-frequency tables will be used to describe demographic and clinical 
parameters. Multivariate analysis of risk factors will be done. Chi-test and 
 
 
23Fisher’s exact will be used to compare categorical variables. 
 
 
Continuous variables will be summarized as mean +/- SD of median and Inter quartile range for non- 
normality distribution of the data. Student t- test and Wilcoxon rank sum test will be used. STATA version 11 
will be used for the data analysis. 95% confidence interval will be calculated for all data. 99mTc-sestamibi 
Gated SPECT myocardial perfusion and 18F-FDG Cardiac PET PerfusioSPnea- 
mgtiemeNnteautsnbmtorsbeliewcsrrmiutohitmfesadetigcnmhtoetnhtes 
astnuadlyyzmeede(Pt1in7egrsfutehsgeimoinne- 
cnmltrueemsdtiaooubdncoeeclldir)sitmpeermirafuissmioantch (viable s(eng=m2e1n5t0s)) (norne- 
dviuacbeled speegrfmuseinotns) (n(n==4203162)) reports of consecutive patients from January 2009 and 
June 2015 Segments without (n=240) Table 1 Baseline 
 
 
1characteristics  of patients according to myocardial viability Variable Overall 
population (n= 236) Myocardial viability p-value No (n= 
 
 
91) (38.6%) Yes (n=145) (61.4%) Age (years) 59.1 SD 11.0 57.7 SD 11.4 60.0 SD 10.7 0.163 20-39 11 (4.7) 
5 (5.5) 6 (4.1) 40-49 36 (15.3) 16 (17.6) 20 (13.8) 50-59 70 ( 29.7) 33 (36.3) 37 (25.5) 60-69 78 (33.1) 22 
(24.2) 56 (38.6) 70+ 41 (17.4) 15 (16.5) 26 (17.9) Male 194 (82.2) 75 (82.4) 119 (82.1) 0.524 Ethnicity: 0.164 
White 125 (53.0) 56 (61.5) 69 (47.6) Indian 71 (30.1) 21 (23.1) 50 (34.5) Black 32 (13.6) 12 (13.2) 20 (13.8) 
Cardiovascular risk factors: Hypertension 114 (48.3) 33 (36.3) 81 (55.9) 0.003 Diabetes Mellitus 61 (25.9) 17 
(18.7) 44 (30.3) 0.046 Dyslipidaemia 91 (38.6) 28 (30.8) 63 (43.5) 0.051 Smoking 91 (38.6) 34 (37.4) 57 
(39.3) 0.765 Family history of CAD 58 (24.6) 17 (18.7) 41 (28.3) 0.096 HIV 4 (1.7) 2 (2.2) 2 (1.4) 0.635 
Concomitant medication: Beta Blockers 103 (43.6) 29 (31.9) 74 (51.0) 0.004 Aspirin 99 (42.0) 27 (29.7) 72 
(49.7) 0.002 Statins 95 (40.3) 27 (29.7) 68 (46.9) 0.009 ACE Inhibitor 76 (32.2) 24 (26.4) 52 (35.9) 0.129 
Calcium Channel Blocker 62 (26.3) 19 (20.9) 43 (29.7) 0.136 Nitrates 45 (19.1) 13 (14.3) 32 (22.1) 0.138 
Regional wall motion: Akinesia 65 (27.5) 29 (31.9) 36 (24.8) 0.239 Dyskinesia 80 (34.0) 24 (26.4) 56 (38.6) 
0.053 Global hypokinesia 124 (52.5) 49 (53.9) 75 (51.7) 0.751 Resting LVEF (SPECT): 28.9 SD 11.4 27.1 
SD 10.4 30 SD 11.8 0.123 LVEF ≥ 50 15 (6.4) 4 (4.4) 11 (7.6) LVEF = 41-49 25 (10.6) 5 (5.5) 20 (13.8) LVEF 
= 36-40 22 (9.3) 8 (8.8) 14 (9.7) LVEF ≤ 35 168 (71.2) 70 (76.9) 98 (67.6) 
 
 
1Data are shown as mean, standard deviation (SD) for continuous variables 
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and absolute numbers (percentage) for dichotomous variables. CAD: 
 
coronary 
 
 
artery disease; ACE: HIV: Human Immunodeficiency Virus; Angiotensin Converting Enzyme; 
 
 
19SPECT: single photon emission tomography; LVEF: left ventricular 
ejection fraction 
 
 
Table 2 Segments with viable myocardium Segment Overall population (n=236) Myocardial viability p-value 
No (n=91) (38.6%) Yes (n=145 ) (61.4%) Apex 187 (79.2) 67 (73.6) 120 (82.8) 0.092 Anterior wall: Apical 
anterior 163 (69.1) 60 (65.9) 103 (71.0) 0.409 Mid anterior 136 (57.6) 48 (52.8) 88 (60.7) 0.229 Basal 
anterior 55 (23.3) 17 (18.7) 38 (26.2) 0.183 Septal wall: Apical septal 121 (51.3) 49 (53.9) 72 (49.7) 0.531 
Mid anteroseptal 132 (55.9) 48 (52.8) 84 (57.9) 0.435 Basal anteroseptal 91 (38.6) 30 (33.0) 61 (42.1) 0.162 
Mid inferoseptal 111 (47.0) 39 (42.9) 72 (49.7) 0.308 Basal inferoseptal 100 (42.4) 30 (33.0) 70 (48.3) 0.021 
Lateral wall: Apical lateral 79 (33.5) 26 (28.6) 53 (36.6) 0.206 Mid anterolateral 47 (19.9) 16 (17.6) 31 (21.4) 
0.477 Basal anterolateral 29 (12.3) 8 (8.8) 21 (14.5) 0.195 Mid inferolateral 69 (29.2) 23 (25.3) 46 (31.7) 
0.289 Basal inferolateral 70 (29.7) 23 (25.3) 47 (32.4) 0.243 Inferior wall: Apical inferior 194 (82.2) 75 (82.4) 
119 (82.1) 0.946 Mid inferior 145 (61.4) 48 (52.8) 97 (66.9) 0.030 Basal inferior 133 (56.4) 45 (49.5) 88 
(60.7) 0.090 Data shown as absolute numbers (percentage) Table 3 
 
 
1Multivariable Logistic Regression Analysis Independent predictors of 
myocardial viability Variables OR 95% CI Z 
 
 
p-value Hypertension 0.26 0.12 – 0.58 -3.28 0.001 Diabetes mellitus 0.75 0.30 – 1.86 -0.62 0.534 
Dyslipidaemia 0.94 0.41 – 2.18 -0.14 0.890 Smoking 2.31 1.01 – 5.29 1.98 0.048 Family history of CAD 0.81 
0.32 – 2.02 -0.45 0.650 Aspirin 0.37 0.16 – 0.83 -2.40 0.016 Dyskinesia 0.50 0.23 – 1.07 -1.80 0.073 CAD; 
coronary artery disease 1 5 7 11 13 14 15 16 17 18 19 20 21 22 23 24 25 26 
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